{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-005136","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.764131+00:00","generated_at":"2026-06-16T18:04:30.844846+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Palatin presents preclinical data for PL9588 glaucoma candidate at ARVO; shows IOP reduction in rabbits","bullets":["Topically administered PL9588 reduced intraocular pressure (IOP) in normotensive rabbits.","IOP reduction magnitude similar or greater than FDA-approved drugs latanoprost and timolol.","Single topical dose of PL9588 lowered IOP for 24 hours.","PL9588 is a melanocortin agonist; data supports continued development for once-daily glaucoma treatment.","Company plans to move into clinical development pending available resources."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-005136","json":"https://secwatch.observer/filing/0001654954-23-005136.json","markdown":"https://secwatch.observer/filing/0001654954-23-005136.md","text":"https://secwatch.observer/filing/0001654954-23-005136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423005136/0001654954-23-005136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423005136/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T18:04:30.844846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}